Table 1 |
|||
|
Epidemiologic, clinical, laboratory and capillaroscopic features at presentation of early SSc and UCTD patients |
|||
|
Feature |
Early SSc (n = 39) |
UCTD (n = 37) |
P |
|
|
|||
|
Sex: F/M |
38/1 |
36/1 |
ns |
|
Age; years (median; range) |
41 (17 to 73) |
38 (18 to 71) |
ns |
|
RP duration; years (median; range) |
3 (0.5 to 24) |
4 (0.5 to 30) |
ns |
|
Puffy fingers |
4 |
0 |
ns |
|
Arthritis |
0 |
4 |
0.05 |
|
ESR >20 mm/h |
5 |
6 |
ns |
|
Gammaglobulins >1.5 g/dl |
3 |
2 |
ns |
|
C3 <80 mg/dl or C4 <15 mg/dl |
2 |
3 |
ns |
|
ANA + |
38 (97.4) |
37 (100) |
ns |
|
ANA titre (median, range) |
1:640 |
1:640 |
ns |
|
SSc-marker antibodies + |
(1:80 to 1:5,120) |
(1:80 to 1:5,120) |
< 0.0001 |
|
ACA + |
36 (92.3) |
0 |
< 0.0001 |
|
Anti-Scl-70 + |
26 (66.7) |
0 |
0.005 |
|
Anti-Th/To |
8 (20.5) |
0 |
ns |
|
Anti-U1RNP |
1 (2.6) |
0 |
ns |
|
1 (2.6) |
0 |
||
|
NVC SSc pattern |
23 (59) |
0 |
< 0.0001 |
|
Megacapillaries + avascular areas |
19 (48.7) |
0 |
< 0.0001 |
|
Avascular areas or megacapillaries |
4 (10.2) |
0 |
ns |
|
Smoking habit |
17 (43.5) |
13 (35.1) |
|
|
|
|||
|
All data are expressed as numbers and percentages (in brackets), except were otherwise indicated. ACA, anticentromere antibodies; ANA, antinuclear antibodies; ESR, erythrosedimentation rate; F, female; M, male; n, number; NVC, nailfold videocapillaroscopy; RP, Raynaud's phenomenon; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease |
|||
|
Valentini et al. Arthritis Research & Therapy 2012 14:R188 doi:10.1186/ar4019 |
|||
